Characteristics of serum GP73 for patients with hepatitis E and its clinical significances

doi:10.3877/cma.j.issn.1674-1358.2018.02.016

Abstract

Abstract:

Objective

To investigate the variable characteristics of serum GP73 for patients with hepatitis E.

Methods

The changes of GP73 level in serum of 80 healthy subjects (control group) and 66 patients with hepatitis E were detected by quantitative enzyme-linked immunosorbent assay.

Results

The median level of serum GP73 for patients with hepatitis E (80.06 ± 52.33 ng/ml) was significantly increased than that of 80 healthy control subjects (38.82 ± 15.67 ng/ml), with significant difference (t = 6.785, P < 0.0001). The level of serum GP73 in patients with hepatitis E had positive correlation with the serum activity of alanine aminotransferase (ALT) (r = 0.28, P = 0.015), aspartate aminotransferase (AST) (r = 0.36, P = 0.002) and the level of serum total bilirubin (TBil) (r = 0.47, P < 0.001). While it had negative correlation with the prothrombin time activity (PTA) (r =-0.329, P = 0.004).

Conclusions

The possibility of acute hepatitis E infection should be considered for those who with significangly elevated serum GP73. Serum GP73 levels in patients with hepatitis E may be correlated with liver damage.

Key words: Hepatitis E, Golgi protein 73, Liver injury, Diagnosis

Yu Jiang, Xu Fei, Julong Hu, Wenhao Hua, Ping Li, Hongshan Wei. Characteristics of serum GP73 for patients with hepatitis E and its clinical significances[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(02): 179-182.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2018.02.016

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2018/V12/I02/179

Figures/Tables 2

References 22

[1]	Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene,2000,249(1-2):53-65.
[2]	Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol,2005,43(6):1007-1012.
[3]	Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut,2010,59(12):1687-1693.
[4]	冯志刚, 岑晓红, 云俊木, 等. GP73在酒精性肝病中的临床意义[J]. 国际检验医学杂志,2015,36(15):2214-2215, 2217.
[5]	魏红山, 康艳芳, 郝晓花, 等. 肝细胞脂肪变对血清糖蛋白GP73水平的影响[J]. 中华实验和临床病毒学杂志,2013,27(4):244-247.
[6]	翟庆玲, 刘燃, 王智强, 等. 自身免疫性肝病患者血清GP73变化特征[J]. 中华实验和临床病毒学杂志,2014,28(4):268-271.
[7]	Wei H, Li B, Zhang R, et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections[J]. PLoS One,2013,8(2):e53862.
[8]	Hu L, Yao W, Wang F, et al. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion[J]. PLoS One,2014,9(3):e90553.
[9]	Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma[J]. Am J Gastroenterol,2004,99(6):1096-1098.
[10]	Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J]. Digestion,2011,83(1-2):83-88.
[11]	Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation[J]. Asian Pac J Cancer Prev,2014,15(4):1539-1544.
[12]	Özkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J]. Digestion,2010,83(1-2):83-88.
[13]	Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol,2010,45(12):1272-1282.
[14]	Kristiansen G, Fritzsche FR, Wassermann K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics[J]. Br J Cancer,2008,99(6):939-948.
[15]	Zhang F, Gu Y, Li X, et al. Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue[J]. Clin Biochem,2010,43(12):983-991.
[16]	Wright LM, Huster D, Lutsenko S, et al. Hepatocyte GP73 expression in Wilson disease[J]. J Hepatol,2009,51(3):557-564.
[17]	Wei H, Hao X, Li B, et al. GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy[J]. Mol Biol Rep,2013,40(11):6397-6405.
[18]	Bao YX, Cao Q, Yang Y, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC)[J]. Diagn Pathol,2013,8:197..
[19]	Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol, 2004,99(6):1087-1095.
[20]	Qiao Y, Chen J, Li X, et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection[J]. Clin Biochem,2014,47(16-17):216-222.
[21]	Wei H, Zhang J, Li H, et al. GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections[J]. Diagn Microbiol Infect Dis,2014,79(1):19-24.
[22]	Wang F, Li Z, Li L, et al. GP73 was upregulated in PBMC stimulated with ConA but failed to promote lymphocyte proliferation[J]. Cell Biol Int,2015,39(3):334-340.

Please choose a citation manager

Content to export